Knowledge HQ

Case Studies

Lovo Integral to COVID-19 Lung Fibrosis Clinical Trial

In this case study we interview Arindam Mitra, Head of Advanced Therapies Manufacturing at Guy's and St. Thomas, Biomedical Research Center, on their use of the Lovo cell processing system to support manufacturing of a COVID-19 cell therapy to treat lung fibrosis. This cell therapy is currently in clinical trials. A BBC video describing the manufacturing procedure and treatment impact on one patient is included.
Read More
Case Studies

Transition to Closed-system T Cell Expansion Leads to Process Optimization

In this case study, ScaleReady helped an autologous T cell therapy company rapidly transition to a closed-system process for cell expansion by providing a testing plan to verify that G-Rex500M-CS closed-system bioreactors would meet their immediate cell production requirements and improve cell production efficiency, while adhering to their short timelines for going into clinical trials. In doing so, the company also uncovered small changes to their cell culture protocols that made a big impact on their cell production efficiency.
Read More
Case Studies

Forecasting a Commercially Viable T Cell Therapy Manufacturing Process

In this case study, a company requested help from ScaleReady to build business case for G-Rex®500M-CS bioreactors as the primary cell production platform for their autologous TCR T cell therapy pipeline. ScaleReady modeled operational costs for an autologous TCR T cell therapy company using G-Rex bioreactors. This provided transparency into long-term commercial viability of the ScaleReady platform.
Read More
Case Studies

GMP Cytokines Optimization for Closed System T Cell Therapy Manufacturing

In this case study, a company focused on autologous T cell therapies targeting solid tumor cancers was progressing into clinical trials and needed to transition from research-grade to GMP-grade cytokines. Concurrently they wanted to improve their methods of cytokine supplementation to reduce cytokine waste, improve dose accuracy across lots, and reduce process risk by defining methods for closed-system cytokine addition. ScaleReady detailed a plan to help them achieve these goals.
Read More